A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

BACKGROUND: Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirooka, Yoshiki, Kasuya, Hideki, Ishikawa, Takuya, Kawashima, Hiroki, Ohno, Eizaburo, Villalobos, Itzel B., Naoe, Yoshinori, Ichinose, Toru, Koyama, Nobuto, Tanaka, Maki, Kodera, Yasuhiro, Goto, Hidemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970460/
https://www.ncbi.nlm.nih.gov/pubmed/29801474
http://dx.doi.org/10.1186/s12885-018-4453-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970460/
https://www.ncbi.nlm.nih.gov/pubmed/29801474
http://dx.doi.org/10.1186/s12885-018-4453-z

Ejemplares similares